Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Q1 25

Dallas, Texas--(Newsfile Corp. - June 4, 2025) - Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path Holdings, Inc. (OTCQB: BPTH) is a clinical-stage biotechnology company based in Bellaire, Texas, pioneering RNA interference (RNAi) therapeutics through its proprietary DNAbilize® platform. This innovative technology employs neutral-charge, liposomal delivery of antisense oligonucleotides, enhancing drug stability and cellular uptake while minimizing toxicity. The Company's lead candidate, prexigebersen (BP1001), targets the Grb2 protein and is currently in Phase 2 trials for acute myeloid leukemia (AML). A modified version, BP1001-A, is undergoing Phase 1/1b trials for solid tumors and has shown promise in preclinical studies for obesity and type 2 diabetes. Another candidate, BP1002, targets the Bcl-2 protein and is being evaluated for blood cancers and solid tumors. Bio-Path is also preparing an Investigational New Drug (IND) application for BP1003, a STAT3 inhibitor aimed at treating pancreatic cancer.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
Phase 2 prexigebersen data shows potential for FDA approval in AML treatment.
BP1001-A trial shows early signs of efficacy in advanced solid tumors.
Advancing pipeline backed by strategic R&D and a robust patent portfolio.
Click image above to view full announcement.
About StonegateStonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA), provides a full spectrum of investment banking services for public and private companies.
Contacts: Stonegate Capital Partners (214) 987-4121 info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254522

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

2 hours ago

• Yahoo

WNP Launches All-in-One Hyaluronic Acid Skincare Set, Pioneering a "3-Step Scientific Skincare Method"

Culver City, California--(Newsfile Corp. - June 22, 2025) - Skincare brand WNP officially launched the "All-in-One Hyaluronic Acid Skincare Set" on its website, introducing its original "Three-Step Scientific Skincare Method." The set integrates five key skincare steps - cleansing, hydration, repair, brightening, and early-stage anti-aging - into a comprehensive skincare system based on four core innovations: nano-delivery, HTAC thermal water dynamics, 4D hyaluronic acid, and microencapsulation technology. This set offers a streamlined solution for everyday skincare needs. From cleanse to anti-aging - the complete, science-backed routine for hydrated, balanced, glowing skin. To view an enhanced version of this graphic, please visit: Four Key Innovations Nano-Liposome Delivery WNP utilizes nano-liposome technology to reduce Ceramide NP particle size to below 100 nm, enabling targeted delivery to the basal layer of the stratum corneum. Lab tests show it helps fill intercellular lipid gaps and reduce transepidermal water loss, offering industry-leading repair benefits for sensitive and barrier-damaged skin. HTAC Thermal Decomposition Water Dynamics WNP's toner features Italian patented HTAC technology, which protects red algae and recombinant collagen activity. Tests show it boosts natural hyaluronic acid production by 124% and cellular mitochondrial activity by 229%. 4D Hyaluronic Acid Multi-Layer Hydration Based on Bloomage Biotech's 4D hyaluronic acid formulation, four molecular weights of hyaluronic acid penetrate from the epidermis to the dermis. Combined with a water-in-oil lamellar emulsion structure, this provides deep, lasting hydration. Microencapsulated Time-Release Salicylic Acid Salicylic acid is microencapsulated for sustained release of active ingredients, delivering gentle exfoliation while minimizing irritation. Ideal for daily use on sensitive or combination-oily skin. Five Steps, One Streamlined Routine Gentle Cleansing: A non-soap amino acid cleanser with pH 5.5-6, refined through 45℃ natural crystallization to remove excess emulsifiers. Fine foam gently purifies without residue. Soothing & Hydration: A serum-texture toner that forms a water film on contact. Functions as both mist and toner for instant moisture. Targeted Hydration: 3% Hyaluronic Acid Capsules, a TikTok bestseller, delivers precise hydration without pilling. Brighten & Even: A matrix of niacinamide, SymWhite®377, and vitamin C derivatives to block melanin transfer and fade oxidized spots. Early Anti-Aging: Patented recombinant collagen, triple peptides, and multiple ceramides to rebuild elasticity and visibly firm skin within 28 days. Brand Vision "With this launch, WNP merges cutting-edge nano-delivery with a multi-dimensional hyaluronic hydration system to redefine what 'minimalist skincare' can mean," said WNP's Chief Product Spokesperson-Dr. Emily. "We believe skincare is shifting from ingredient stacking to true tech-enabled performance-and this launch is the clearest expression of that evolution." About WNP WNP (Wake Nature Perfection) is a science-driven skincare brand based in Asia, rooted in the philosophy of precision skincare. It integrates top-tier dermatological research with global innovations in active ingredients. As an industry innovator, WNP has introduced multiple "first-of-its-kind" technologies in both domestic and international markets, committed to delivering safe, effective, and targeted skincare solutions. For more information, please visit Source: WNPContact: MattDepartment: Brand TeamEmail: matt@ To view the source version of this press release, please visit

Business Wire

4 hours ago

• Business Wire

2025 Travelers Championship Generates More Than $4 Million for Charity

HARTFORD, Conn.--(BUSINESS WIRE)--The Travelers Companies, Inc. (NYSE: TRV) today announced that the 2025 Travelers Championship – a PGA TOUR Signature Event – generated more than $4 million for over 215 nonprofits, both record highs. Travelers also set a record this year as the longest-running title sponsor in the tournament's history. In the 19 years the company has been title sponsor, the Travelers Championship has generated tens of millions of dollars for charity. Alan Schnitzer, Chairman and Chief Executive Officer of Travelers, said, 'This week truly captured what makes the Travelers Championship so special – world-class golf played before an enthusiastic crowd, all united by a shared purpose. It is a formula that led to a great week of golf and more money raised for charity than ever before. For 19 years, we have been honored to bring the PGA TOUR to Connecticut, and every year I am inspired by the passion of the players, the dedication of our fans and the incredible support from volunteers and partners who rally around our mission to give back. In addition to supporting vital charitable causes, we are proud that the tournament also generates significant economic activity for the state of Connecticut. Congratulations to our 2025 champion, Keegan Bradley, for rising to the top of one of the strongest fields in the game. We are already looking forward to making next year's tournament even more memorable.' The Travelers Championship donates 100% of its net proceeds to nonprofits. This year's primary beneficiary is The Hole in the Wall Gang Camp, an organization based in Ashford, Connecticut, that provides a traditional summer camp experience for children with serious illnesses. Many other worthy charities – spanning arts and culture, education, health care, housing, human services, mental health, food insecurity, science and technology, and youth development – also benefit from their involvement with the Travelers Championship. Andy Bessette, Executive Vice President and Chief Administrative Officer of Travelers, said, 'The Travelers Championship extends far beyond tournament week. We have created a community of fans that spans the region, and it is because of their support that we are able to make such an impact on so many charities, the true winners of the Travelers Championship. We are so grateful to the world's best PGA TOUR players for delivering another tremendous competition that we will all remember for some time.' The 2026 Travelers Championship is scheduled to take place June 22-28 at TPC River Highlands in Cromwell, Connecticut. For more information, visit About Travelers

Business Upturn

7 hours ago

• Business Upturn

INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Red Cat Holdings, Inc. (RCAT) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

SAN DIEGO, June 22, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Red Cat Holdings, Inc. (NASDAQ: RCAT) securities between March 18, 2022 and January 15, 2025, inclusive (the 'Class Period'), have until Tuesday, July 22, 2025 to seek appointment as lead plaintiff of the Red Cat class action lawsuit. Captioned Olsen v. Red Cat Holdings, Inc. , No. 25-cv-05427 (D.N.J.), the Red Cat class action lawsuit charges Red Cat as well as certain of Red Cat's top current and former executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Red Cat class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Red Cat, together with its subsidiaries, provides products and solutions to drone industry. Red Cat's products include, among others, the 'Teal 2' drone, a small, unmanned aircraft system designed to purportedly 'Dominate the Night' during nighttime military operations. The Red Cat class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Red Cat's Salt Lake City facility's production capacity, and defendants' progress in developing the same, was overstated; and (ii) the overall value of Red Cat's Short Range Reconnaissance Program of Record Tranche 2 contract (the 'SRR Contract') was overstated. The Red Cat class action lawsuit further alleges that on July 27, 2023, Red Cat revealed that its Salt Lake City facility could only currently produce 100 drones per month, the facility was still being built, refined, and expanded, and that construction of the facility was only 'substantially completed' and potentially could reach a production capacity of 1,000 drones per month over the next 2 to 3 years, but only with additional capital investments and manufacturing efficiencies realized. On this news, the price of Red Cat stock fell nearly 9%, according to the complaint. Then, on September 23, 2024, the Red Cat class action lawsuit further alleges that Red Cat announced its financial results for the first quarter of fiscal year 2025, reporting losses per share of $0.17, missing consensus estimates by $0.09, and revenue of $2.8 million, missing consensus estimates by $1.07 million. According to the complaint, Red Cat further disclosed that Red Cat had spent 'the past four months . . . retooling [the Salt Lake City facility] and preparing for high volume production,' while admitting that a 'pause in manufacturing of Teal 2 and building Army prototypes impacted Teal 2 sales' because, among other things, Red Cat 'couldn't produce and sell Teal 2 units while retooling [its] factory.' The Red Cat class action lawsuit alleges that on this news, the price of Red Cat stock fell more than 25%. Finally, the Red Cat class action lawsuit further alleges that on January 16, 2025, Kerrisdale Capital published a report alleging that '[t]he SRR contract that Red Cat won in November and preemptively announced without the Army's permission is much smaller and less favorable than management as intimated,' and that '[i]t's highly implausible that a mass-production facility for manufacturing drones has been built at any point in the last two years for less than $1 million.' On this news, the price of Red Cat stock fell more than 21% over two trading sessions, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Red Cat securities during the Class Period to seek appointment as lead plaintiff in the Red Cat class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Red Cat class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Red Cat class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Red Cat class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]